Physician profile
Wallace E Duff
NPI 1467446799
$8,178.11
in general payments reported to CMS, 2019-2025
26 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $889 · 2021: $1,690 · 2022: $1,561 · 2023: $767 · 2024: $952 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,355.74 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $754.78 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $433.25 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $400.90 | 2021 | |
| Genentech USA, INC. | $364.13 | 2019-2022 | |
| Optinose US, INC. | $341.81 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $318.12 | 2022 | |
| Pfizer INC. | $248.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $238.09 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $225.93 | 2020-2023 | |
| Genzyme Corporation | $206.68 | 2020-2025 | |
| Vertex Pharmaceuticals Incorporated | $188.21 | 2025 | |
| Abbvie INC. | $184.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $177.23 | 2019-2024 | Nucala |
| Teva Pharmaceuticals USA, INC. | $169.41 | 2021-2025 | Ajovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $158.51 | 2019-2021 | |
| Axsome Therapeutics, INC. | $139.37 | 2025 | Symbravo |
| Regeneron Healthcare Solutions, INC. | $73.74 | 2025 | Dupixent |
| Alk-Abello, INC | $48.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.79 | 2019-2020 | |
| Aytu Biopharma, INC. | $25.22 | 2019 | |
| Convatec INC. | $24.40 | 2025 | |
| Bioventus LLC | $19.71 | 2024 | Exogen Ultrasound Bone Healing System |
| Merck Sharp & Dohme LLC | $19.11 | 2023 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Allergan, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.